Envenoming by  snake: a patient with liver cirrhosis presenting disruption of hemostatic balance by unknown
CASE REPORT Open Access
Envenoming by Viridovipera stejnegeri
snake: a patient with liver cirrhosis
presenting disruption of hemostatic
balance
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Abstract
Background: In most cases of envenoming by the green habu Viridovipera stejnegeri in Taiwan coagulopathy is not
observed.
Case presentation: Herein, we describe the case of a patient with liver cirrhosis who developed venom-induced
consumptive coagulopathy after V. stejnegeri bite. Laboratory investigation revealed the following: prothrombin
time > 100 s (international normalized ratio > 10), activated partial thromboplastin time > 100 s, fibrinogen < 50 mg/
dL, and fibrin degradation product > 80 μg/mL. The patient recovered after administration of bivalent hemorrhagic
antivenom, vitamin K, fresh frozen plasma and cryoprecipitate.
Conclusion: The liver, directly involved in the acute phase reaction, is the main responsible for neutralization of
animal toxins. Any patient with history of liver cirrhosis bitten by a venomous snake, even those whose venoms
present low risk of coagulopathy, should be very carefully monitored for venom-induced consumptive
coagulopathy (VICC), since the hemostatic balance may be disrupted.
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Background
Six species of venomous snakes are commonly found in
Taiwan. Most cases of snake envenoming admitted to hos-
pital emergency departments (ED) are caused by Protobo-
throps mucrosquamatus (Taiwan habu) and Viridovipera
stejnegeri (green habu, bamboo viper or Chinese green
tree viper) [1]. The latter is very easily distinguishable
from other species because of its markedly different
color pattern. Unlike other species that are brown,
black or white, V. stejnegeri has a unique color charac-
teristic, its dorsal scales are bright to dark green
whereas its ventral scales are white to pale green and
its tail is reddish. V. stejnegeri bites provoke less se-
vere clinical effects than the other local species. For
example, systemic coagulopathy is extremely rare after
V. stejnegeri envenoming [2]. Venom-induced con-
sumptive coagulopathy (VICC) has been introduced
for a more general description of this type of systemic
coagulopathy [3]. Herein, we present a rare case of a
patient with liver cirrhosis who developed VICC after
V. stejnegeri envenoming.
Case presentation
A 47-year-old man was bitten by a venomous snake on
his right index finger at his home, in a mountainous
area, when he was trying to get rid of the animal. One
hour after the bite, he was sent to a local hospital for
first aid. The staff of the hospital showed pictures of
snakes to the patient, who identified the snake that had
bitten him as Viridovipera stejnegeri (Fig. 1).
Then, the man received four vials of bivalent
hemorrhagic antivenom. Because of pain and swelling
on the right hand and elbow, he was transferred to our
ED for further treatment. Initial clinical examination
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revealed stable vital signs with a normal level of con-
sciousness. No dyspnea or muscle weakness was observed.
However, swelling and tenderness were observed on his
right index finger and elbow. A fang mark was observed
on the right index finger. On arrival to the ED, laboratory
investigation revealed a platelet count of 142,000/μL,
prothrombin time (PT) >100 s (international normalized
ratio > 10), and activated partial thromboplastin time
(APTT) > 100 s (Table 1). Both creatinine and bilirubin
levels were normal. We found that he had been a hepatitis
C virus carrier for several years. He also had liver cirrhosis,
Child–Pugh score A and diabetes mellitus. A surgical his-
tory of splenectomy and left nephrectomy caused by a
trauma accident 10 years ago was also noted. He was
under outpatient follow up of the gastroenterology depart-
ment without coagulopathy noted before this episode of
snake envenoming. Two vials of bivalent hemorrhagic
antivenom were given. Blood transfusion with two units of
fresh frozen plasma (FFP) and one vial of vitamin K
(10 mg) were administered. Fluid replacement therapy
with isotonic normal saline (0.9%) was also used for
treatment.
The patient was admitted to the general ward and
continued to receive antivenom, vitamin K and FFP
until the PT level improved. On day 5, the fibrinogen
level was low at < 50 mg/dL, and the fibrin degradation
product (FDP) was > 80 μg/mL. Cryoprecipitate was
given for several days until the fibrinogen level im-
proved. The local toxic effect on the right hand im-
proved. He was discharged on day 9. The man
returned to our outpatient department 2 weeks after
the snakebite. The laboratory data revealed that PT,
APTT, fibrinogen and FDP were all within the normal
range. He returned to work 1 week later. He was under
outpatient department follow up and the laboratory
data of PT, APTT, albumin and bilirubin level were all
within normal range 1 year later.
Discussion
Approximately 40 cases of snakebite are admitted to
Chang-Gung Memorial Hospital, Keelung branch in Taiwan
every year. Most events are observed during summer and
fall, whereas the areas where they are mostly like to occur
are farms, gardens or yards in mountainous regions. When
a snakebite patient is sent to our ED, the first step is to con-
firm the snake species. Subsequently, we will give the ap-
propriate antivenom depending on the species. In Taiwan,
the available antivenom is equine F (ab′) 2 manufactured
by the Centers for Disease Control (CDC) of Taiwan [4].
Most cases of envenoming referred to our hospital are
caused by P. mucrosquamatus and V. stejnegeri snakes. P.
mucrosquamatus envenoming is associated with more ser-
ious local and systemic complications, such as VICC,
acute renal failure and rhabdomyolysis, in comparison
with V. stejnegeri envenoming [2]. The toxins of P.
mucrosquamatus and V. stejnegeri venoms contain phos-
pholipases A2 (PLA2), metalloproteinases, serine protein-
ases and C-type lectin-like related proteins [5]. PLA2 is an
anticoagulant enzyme that can cause extrinsic coagulation
pathway inhibition by inhibiting extrinsic tenase complex
and prothrombinase complex [6, 7]. Metalloproteinases
are fibrinongenases that can destroy fibrinogen and serine
proteinases, such as protein C activators, can inhibit co-
agulation. C-type lectin-like related proteins can inhibit
prothrombinase activation, causing anticoagulation [8]. P.
mucrosquamatus venom has a much stronger anticoagu-
lant effect than that of V. stejnegeri [9]. In Taiwan,V. stej-
negeri envenoming rarely causes VICC [2]. Only one study
reported that V. stejnegeri envenoming may have caused a
disseminated intravascular coagulation-like syndrome in
south China [10].
In our case, the patient was a hepatitis C virus carrier,
consumed alcohol and had liver cirrhosis, Child–Pugh
Fig. 1 The color pattern of Viridovipera stejnegeri (green habu) is
bright to dark green on the dorsal side and pale green to whitish on
the ventral side
Table 1 Time course of envenoming (biochemical parameters)
since the bite until hospital discharge








Day 1 >100 >10 >100 142
Day 2 29.8 2.71 29.4
Day 3 >100 >10
Day 4 >100 >10 29 159
Day 5 >100 >10 28.3 <50 >80 1.63
Day 6 12 1.15 26.4 172 65 >80
Day 7 12.2 1.17 80 >80
Day 9 11.4 1.1 122 >80
Day 14 9.7 0.95 401 284 <10
PT prothrombin time, INR international normalized ratio, Plt platelet, APTT
activated partial thromboplastin time, FDP fibrin degradation product
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score A. He developed VICC after V. stejnegeri enve-
noming. The liver, directly involved in the acute phase
reaction, is the main organ that neutralizes animal
toxins [11–14]. It is the predominant site for producing
the coagulation factors including fibrinogen (factor I),
prothrombin (factor II), upstream factors V, VII, IX, X
and XI and anticoagulant proteins. The liver produces
some inhibitors of coagulation, including protein S, pro-
tein C, antithrombin and fibrinolytic factors. Stable liver
cirrhosis may maintain rebalanced hemostasis because
both procoagulant factors and fibrinolytic proteins are
deficient [15]. An unstable hemostatic balance can be
disrupted by acute phase reaction, such as infection and
inflammation, and oxidative stress induced by the venom
[12, 13, 16, 17].
In our patient, highly elevated PT (>100 s) and APTT
(>100 s) levels were detected, possibly because of snake
envenoming and liver coagulation factor deficiency.
We suspected that V. stejnegeri envenoming disrupted
the rebalanced hemostasis. He initially had mild
thrombocytopenia (142,000/μL), which gradually im-
proved, possibly because of his history of splenectomy,
which may have been responsible for splenic sequestration
of platelets. We gave him bivalent hemorrhagic antivenom
to neutralize the toxins and FFP and vitamin K to correct
coagulopathy. His fibrinogen level was low (<50 mg/dL)
on day 5, therefore cryoprecipitate transfusions were ne-
cessary. Edema and swelling were initially observed in his
local wound, but gradually improved. He easily developed
skin ecchymosis at the intravenous injection site.
Only a few studies have discussed V. stejnegeri enve-
noming in patients with liver cirrhosis. VICC is ex-
tremely rare in patients bitten by V. stejnegeri. Balanced
hemostasis in patients with liver cirrhosis who are
attacked by venomous snakes may be disrupted, and
these patients should be very carefully monitored to
avoid catastrophic hemorrhage complications. The use
of clotting factors such as FFP or cryoprecipitate to
treat VICC without bleeding is still controversial [18].
However, patients with liver cirrhosis cannot resyn-
thesize coagulation factors as rapidly as healthy ones.
Early replacement of clotting factors after antivenom
treatment can ensure early recovery of clotting func-
tion [19].
Conclusions
V. stejnegeri envenoming is associated with a relatively
low risk of VICC in Taiwan. However, any patient with a
history of liver cirrhosis who is bitten by a venomous
snake should be very carefully monitored for VICC. The
likelihood of VICC may be higher in such patients. We
must evaluate closely the laboratory data and symptoms.
Such patients should be observed for 24 h, and labora-
tory data should be followed up to determine whether
VICC has occurred. In case of VICC, patients should be
admitted for treatment until improvement of clotting
function.
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